Avicidin cancer therapy data

NERX reported on nine of 11 patients enrolled in the dosimetry monitoring portion of its Phase I trial, announcing an eight-fold improvement in the tumor-to-blood ratio with pre-targeting, compared to conventional use of its anti-tumor antibody.

Previous work with the anti-NR-Leu-10 antibody gave tumor regressions, but bone marrow toxicity developed. Pre-targeting will avoid the toxicity by allowing less radiolabel to remain in the body, NERX said. ...